A novel, externally validated inflammation-based prognostic algorithm in hepatocellular carcinoma: The prognostic nutritional index (PNI)

British Journal of Cancer

Volumn 106, Issue 8, 2012, Pages 1439-1445

  Pinato, D J ^a,b   North, B V ^c   Sharma, R ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

hepatocellular carcinoma; inflammation; prognosis; prognostic index; survival

Indexed keywords

ALBUMIN; ALPHA FETOPROTEIN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CANCER STAGING; COHORT ANALYSIS; DEMOGRAPHY; FEMALE; HUMAN; INFLAMMATION; LIVER CELL CARCINOMA; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NUTRITIONAL ASSESSMENT; OVERALL SURVIVAL; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; PROGNOSTIC NUTRITIONAL INDEX; SURVIVAL PREDICTION; UNIVARIATE ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; FEMALE; HUMANS; INFLAMMATION; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NUTRITION ASSESSMENT; PROGNOSIS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84859632722     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.92     Document Type: Article

References (58)

1. Andreyev HJ, Norman AR, Oates J, Cunningham D (1998) Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? Eur J Cancer 34(4): 503-509 (Pubitemid 28179346)
2. Argiles JM, Busquets S, Lopez-Soriano FJ (2003a) Cytokines in the pathogenesis of cancer cachexia. Curr Opin Clin Nutr Metab Care 6(4): 401-406 (Pubitemid 40684591)
3. Argiles JM, Moore-Carrasco R, Fuster G, Busquets S, Lopez-Soriano FJ (2003b) Cancer cachexia: the molecular mechanisms. Int J Biochem Cell Biol 35(4): 405-409 (Pubitemid 36140062)
4. Berasain C, Castillo J, Perugorria MJ, Latasa MU, Prieto J, Avila MA (2009) Inflammation and liver cancer: new molecular links. Ann NY Acad Sci 1155: 206-221
5. Bruix J, Sherman M (2005) Management of hepatocellular carcinoma. Hepatology 42(5): 1208-1236 (Pubitemid 43112690)
6. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodés J (2001) Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference. J Hepatol 35(3): 421-430 (Pubitemid 32844200)
7. Camma C, Cabibbo G (2009) Prognostic scores for hepatocellular carcinoma: none is the winner. Liver Int 29(4): 478-480
8. Canna K, McArdle PA, McMillan DC, McNicol AM, Smith GW, McKee RF, McArdle CS (2005) The relationship between tumour T-lymphocyte infiltration, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer. Br J Cancer 92(4): 651-654 (Pubitemid 40460599)
9. Carvalho L, Parise ER (2006) Evaluation of nutritional status of nonhospitalized patients with liver cirrhosis. Arquivos de Gastroenterologia 43(4): 269-274 (Pubitemid 46556124)
10. Charles KA, Rivory LP, Brown SL, Liddle C, Clarke SJ, Robertson GR (2006) Transcriptional repression of hepatic cytochrome P450 3A4 gene in the presence of cancer. Clin Cancer Res Official J Am Assoc Cancer Res 12(24): 7492-7497 (Pubitemid 46095425)
11. Chen TM, Lin CC, Huang PT, Wen CF (2011) Neutrophil-to-lymphocyte ratio associated with mortality in early hepatocellular carcinoma patients after radiofrequency ablation. J Gastroenterol Hepatol 27(3): 553-561
12. Dewys WD, Begg C, Lavin PT, Band PR, Bennett JM, Bertino JR, Cohen MH, Douglass Jr HO, Engstrom PF, Ezdinli EZ, Horton J, Johnson GJ, Moertel CG, Oken MM, Perlia C, Rosenbaum C, Silverstein MN, Skeel RT, Sponzo RW, Tormey DC (1980) Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med 69(4): 491-497 (Pubitemid 10018703)
13. Ellis MC, Cassera MA, Vetto JT, Orloff SL, Hansen PD, Billingsley KG (2011) Surgical treatment of intrahepatic cholangiocarcinoma: outcomes and predictive factors. HPB Official J Int Hepato Pancreato Biliary Assoc 13(1): 59-63
14. El-Serag HB, Marrero JA, Rudolph L, Reddy KR (2008) Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 134(6): 1752-1763 (Pubitemid 351615415)
15. Esper DH, Harb WA (2005) The cancer cachexia syndrome: a review of metabolic and clinical manifestations. Nutr Clin Pract 20(4): 369-376 (Pubitemid 47050807)
16. Falleti E, Fabris C, Toniutto P, Fontanini E, Cussigh A, Bitetto D, Fumolo E, Fornasiere E, Bragagnini W, Pinato DJ, Minisini R, Pirisi M (2009) Interleukin-6 polymorphisms and gender: relationship with the occurrence of hepatocellular carcinoma in patients with end-stage liver disease. Oncology 77(5): 304-313
17. Fujiwara Y, Shiba H, Furukawa K, Iida T, Haruki K, Gocho T, Wakiyama S, Hirohara S, Ishida Y, Misawa T, Ohashi T, Yanaga K (2010) Glasgow prognostic score is related to blood transfusion requirements and post-operative complications in hepatic resection for hepatocellular carcinoma. Anticancer Res 30(12): 5129-5136
18. Gomez D, Farid S, Malik HZ, Young AL, Toogood GJ, Lodge JP, Prasad KR (2008) Preoperative neutrophil-to-lymphocyte ratio as a prognostic predictor after curative resection for hepatocellular carcinoma. World J Surg 32(8): 1757-1762
19. Halazun KJ, Hardy MA, Rana AA, Woodland DCT, Luyten EJ, Mahadev S, Witkowski P, Siegel AB, Brown Jr RS, Emond JC (2009) Negative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma. Ann Surg 250(1): 141-151
20. Hao K, Luk JM, Lee NP, Mao M, Zhang C, Ferguson MD, Lamb J, Dai H, Ng IO, Sham PC, Poon RT (2009) Predicting prognosis in hepatocellular carcinoma after curative surgery with common clinicopathologic parameters. BMC Cancer 9: 389
21. Harrell FE (2001) Regression Modeling Strategies. Springer: New York
22. Hashimoto K, Ikeda Y, Korenaga D, Tanoue K, Hamatake M, Kawasaki K, Yamaoka T, Iwatani Y, Akazawa K, Takenaka K (2005) The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma. Cancer 103(9): 1856-1864 (Pubitemid 40563258)
23. Hsu CY, Hsia CY, Huang YH, Su CW, Lin HC, Lee PC, Loong CC, Chiang JH, Huo TI, Lee SD (2010) Selecting an optimal staging system for hepatocellular carcinoma: comparison of 5 currently used prognostic models. Cancer 116(12): 3006-3014
24. Huitzil-Melendez FD, Capanu M, O'Reilly EM, Duffy A, Gansukh B, Saltz LL, Abou-Alfa GK (2010) Advanced hepatocellular carcinoma: which staging systems best predict prognosis? J Clin Oncol 28(17): 2889-2895
25. Investigators CLIP (1998) A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 28(3): 751-755
26. Ishizuka M, Kubota K, Kita J, Shimoda M, Kato M, Sawada T (2011) Impact of an inflammation-based prognostic system on patients undergoing surgery for hepatocellular carcinoma: a retrospective study of 398 Japanese patients. Am J Surg 203(1): 101-106
27. Jagoe RT, Goodship TH, Gibson GJ (2001) Nutritional status of patients undergoing lung cancer operations. Ann Thorac Surg 71(3): 929-935 (Pubitemid 32210404)
28. Jee SH, Shen SC, Chiu HC, Tsai WL, Kuo ML (2001) Overexpression of interleukin-6 in human basal cell carcinoma cell lines increases antiapoptotic activity and tumorigenic potency. Oncogene 20(2): 198-208
29. Kanda M, Fujii T, Kodera Y, Nagai S, Takeda S, Nakao A (2011) Nutritional predictors of postoperative outcome in pancreatic cancer. Br J Surg 98(2): 268-274
30. Kemik O, Sumer A, Kemik AS, Hasirci I, Purisa S, Dulger AC, Demiriz B, Tuzun S (2010) The relationship among acute-phase response proteins, cytokines and hormones in cachectic patients with colon cancer. World J Surg Oncol 8: 85
31. Kinoshita T, Ito H, Miki C (1999) Serum interleukin-6 level reflects the tumor proliferative activity in patients with colorectal carcinoma. Cancer 85(12): 2526-2531 (Pubitemid 29272736)
32. Kuang DM, Zhao Q, Wu Y, Peng C, Wang J, Xu Z, Yin XY, Zheng L (2011) Peritumoral neutrophils link inflammatory response to disease progression by fostering angiogenesis in hepatocellular carcinoma. J Hepatol 54(5): 948-955
33. Lai CC, You JF, Yeh CY, Chen JS, Tang R, Wang JY, Chin CC (2011) Low preoperative serum albumin in colon cancer: a risk factor for poor outcome. Int J Colorectal Dis 26(4): 473-481
34. Llovet JM, Bru C, Bruix J (1999) Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19(3): 329-338
35. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4): 378-390
36. McKeown DJ, Brown DJ, Kelly A, Wallace AM, McMillan DC (2004) The relationship between circulating concentrations of C-reactive protein, inflammatory cytokines and cytokine receptors in patients with non-small-cell lung cancer. Br J Cancer 91(12): 1993-1995 (Pubitemid 40128764)
37. McMillan DC (2009) Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care 12(3): 223-226
38. Meng QH, Yu HW, Li J, Wang JH, Ni MM, Feng YM, Jin Y, Hou W, Yu SQ, Wang X, Liu Y (2010) Inadequate nutritional intake and protein-energy malnutrition involved in acute and chronic viral hepatitis Chinese patients especially in cirrhosis patients. Hepatogastroenterology 57(101): 845-851
39. Murry DJ, Riva L, Poplack DG (1998) Impact of nutrition on pharmacokinetics of anti-neoplastic agents. Int J Cancer Suppl 11: 48-51
40. Nagaoka S, Yoshida T, Akiyoshi J, Akiba J, Torimura T, Adachi H, Kurogi J, Tajiri N, Inoue K, Niizeki T, Koga H, Imaizumi T, Kojiro M, Sata M (2007) Serum C-reactive protein levels predict survival in hepatocellular carcinoma. Liver Int 27(8): 1091-1097 (Pubitemid 47399443)
41. Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM, Karin M (2007) Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 317(5834): 121-124 (Pubitemid 47056470)
42. Nouso K, Kobayashi Y, Nakamura S, Kobayashi S, Toshimori J, Kuwaki K, Hagihara H, Onishi H, Miyake Y, Ikeda F, Shiraha H, Takaki A, Iwasaki Y, Kobashi H, Yamamoto K (2010) Evolution of prognostic factors in hepatocellular carcinoma in Japan. Aliment Pharmacol Ther 31(3): 407-414
43. Nozoe T, Kimura Y, Ishida M, Saeki H, Korenaga D, Sugimachi K (2002) Correlation of pre-operative nutritional condition with post-operative complications in surgical treatment for oesophageal carcinoma. Eur J Surg OncolJ Eur Soc Surg Oncol Br Assoc Surg Oncol 28(4): 396-400
44. Nozoe T, Ninomiya M, Maeda T, Matsukuma A, Nakashima H, Ezaki T (2010) Prognostic nutritional index: a tool to predict the biological aggressiveness of gastric carcinoma. Surg Today 40(5): 440-443
45. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55(2): 74-108 (Pubitemid 40372904)
46. Prieto J (2008) Inflammation, HCC and sex: IL-6 in the centre of the triangle. J Hepatol 48(2): 380-381
47. Proctor MJ, Morrison DS, Talwar D, Balmer SM, Fletcher CD, O'Reilly DS, Foulis AK, Horgan PG, McMillan DC (2011) A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. Eur J Cancer 47(17): 2633-2641
48. Ray-Coquard I, Cropet C, Van Glabbeke M, Sebban C, Le Cesne A, Judson I, Tredan O, Verweij J, Biron P, Labidi I, Guastalla JP, Bachelot T, Perol D, Chabaud S, Hogendoorn PC, Cassier P, Dufresne A, Blay JY (2009) Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res 69(13): 5383-5391
49. Read JA, Choy ST, Beale PJ, Clarke SJ (2006) Evaluation of nutritional and inflammatory status of advanced colorectal cancer patients and its correlation with survival. Nutr Cancer 55(1): 78-85 (Pubitemid 44477048)
50. Read JA, Crockett N, Volker DH, MacLennan P, Choy ST, Beale P, Clarke SJ (2005) Nutritional assessment in cancer: comparing the Mini-Nutritional Assessment (MNA) with the scored Patient-Generated Subjective Global Assessment (PGSGA). Nutr Cancer 53(1): 51-56 (Pubitemid 43068553)
51. Rey-Ferro M, Castano R, Orozco O, Serna A, Moreno A (1997) Nutritional and immunologic evaluation of patients with gastric cancer before and after surgery. Nutrition 13(10): 878-881 (Pubitemid 27469118)
52. Reynes G, Vila V, Martin M, Parada A, Fleitas T, Reganon E, Martinez-Sales V (2011) Circulating markers of angiogenesis, inflammation, and coagulation in patients with glioblastoma. J Neurooncol 102(1): 35-41
53. Rivory LP, Slaviero KA, Clarke SJ (2002) Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response. Br J Cancer 87(3): 277-280
54. Steel DM, Whitehead AS (1994) The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid A protein. Immunol Today 15(2): 81-88 (Pubitemid 24049801)
55. Tsai AC, Hsu WC, Chan SC, Chang TL (2011) Usefulness of the mini nutritional assessment in predicting the nutritional status of patients with liver cancer in Taiwan. Nutr Cancer 63(3): 334-341
56. Ueno S, Tanabe G, Sako K, Hiwaki T, Hokotate H, Fukukura Y, Baba Y, Imamura Y, Aikou T (2001) Discrimination value of the new western prognostic system (CLIP score) for hepatocellular carcinoma in 662 Japanese patients. Cancer of the Liver Italian Program. Hepatology 34(3): 529-534
57. Yang ZQ, Yang ZY, Zhang LD, Ping B, Wang SG, Ma KS, Li XW, Dong JH (2010) Increased liver-infiltrating CD8+FoxP3+ regulatory T cells are associated with tumor stage in hepatocellular carcinoma patients. Hum Immunol 71(12): 1180-1186
58. Yusuf RZ, Duan Z, Lamendola DE, Penson RT, Seiden MV (2003) Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr Cancer Drug Targets 3(1): 1-19 (Pubitemid 36119417)